TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30591380

Group type: EXPERIMENTAL
Intervention: Mankai
Number of subjects: 36

Group type: COMPARATOR
Intervention: Soft cheese
Number of subjects: 36

Group type: COMPARATOR
Intervention: Green peas
Number of subjects: 36
Study: 27923685

Group type: EXPERIMENTAL
Intervention: LVR with CDCs (Group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: LVR with vehicle solution (Group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vehicle solution without LVR (Group 3)
Number of subjects: 28
Study: 26758937

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24079647

Group type: EXPERIMENTAL
Intervention: Intervention group (4 group sessions)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 83
Study: 23516864

Group type: EXPERIMENTAL
Intervention: Inhalation of phospholipid nanoparticles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18466184

Group type: EXPERIMENTAL
Intervention: Experimental PE program (n=77)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Traditional PE program (n=75)
Number of subjects: 152
Study: 17334939

Group type: EXPERIMENTAL
Intervention: Strengths-based case management intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 162
Study: 15082350

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Late Terlipressin (crossover from placebo)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11437769

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 20
Study: 9667681

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (200 units kg(‐1) day(‐1) plus oral iron supplements 325 mg p.o. t.i.d.)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no r‐HuEPO treatment)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 8065869

Group type: EXPERIMENTAL
Intervention: Low risk criteria for serious bacterial infection (SBI)
Number of subjects: 1057
Study: 2646360

Group type: EXPERIMENTAL
Intervention: Terlipressin (glypressin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31010425

Group type: EXPERIMENTAL
Intervention: Multidisciplinary self-management intervention
Number of subjects: 281
Study: 28283830

Group type: EXPERIMENTAL
Intervention: 5 days of fluoroquinolone treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 days of fluoroquinolone treatment
Number of subjects: 100
Study: 26228536

Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavior Therapy (ABBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both ABBT and AR
Number of subjects: 81
Study: 23773306

Group type: EXPERIMENTAL
Intervention: Maternal verbal scaffolding
Number of subjects: 131
Study: 21982411

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg plus Ezetimibe 10 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dalcetrapib + Ezetimibe
Number of subjects: 22
Study: 18058165

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Overall analysis of original articles
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Quality of reporting
Number of subjects: 1048
Study: 16827019

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation of the maxilla (Group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation of the mandible (Group B)
Number of subjects: 28
Study: 12957566

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 11029965

Group type: EXPERIMENTAL
Intervention: 3 mg Cu‐glycine chelate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 6 mg Cu‐glycine chelate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 mg CuSO4
Number of subjects: 24
Study: 8851594

Group type: EXPERIMENTAL
Intervention: Ceftazidime as intermittent bolus (IB) 2 g i.v. every 8 h (q8h) for 2 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ceftazidime as continuous infusion (CI) 3 g continuous infusion over 24 h for 2 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ceftazidime (both regimens) in presence of tobramycin (4 to 7 mg/kg i.v. q24h)
Number of subjects: 12
Study: 1319982

Group type: EXPERIMENTAL
Intervention: Radiotherapy + alpha interferon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 20
Study: 6703681

Group type: EXPERIMENTAL
Intervention: Ceforanide (1 g every 12 h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cephapirin (2 g every 4 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ceforanide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cephapirin
Number of subjects: 32
Study: 30014664

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tramadol hydrochloride tablets
Number of subjects: 120
Study: 26968285

Group type: EXPERIMENTAL
Intervention: Immediate intramasseteric injection of 2ml of 8mg/2ml dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group received 2ml of sterile saline solution
Number of subjects: 20
Study: 25666690

Group type: EXPERIMENTAL
Intervention: Physical therapy plus TrP‐DN (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical therapy (n = 10)
Number of subjects: 20
Study: 23073338

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with inactivity on fundus fluorescein angiography at month 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with qualitative OCT inactivity at month 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with qualitative OCT inactivity at month 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with leakage on OCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment with inactivity on fundus fluorescein angiography at months 3 and 5
Number of subjects: 0
Study: 20695184

Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation procedure (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No preoperative bowel preparation (Group A)
Number of subjects: 100
Study: 18204341

Group type: EXPERIMENTAL
Intervention: Priming stimulation (twenty 5-second, 6-Hz trains)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-priming (equivalent to priming stimulation)
Number of subjects: 60
Study: 16364548

Group type: EXPERIMENTAL
Intervention: Noxious thermal stimulation (45‐50 degrees C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear of pain questionnaire (FPQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generalized anxiety (indexed by STAI‐T scores)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral thermal stimulation (38 degrees C)
Number of subjects: 0
Study: 14653281

Group type: EXPERIMENTAL
Intervention: Duceram LFC‐Degussa
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Solidex‐Shofu
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Artglass‐Heraeus Kulzer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Targis‐Ivoclar
Number of subjects: 60
Study: 11221150

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) and Fluvoxamine (FVX)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluvoxamine (FVX) alone
Number of subjects: 42
Study: 9095122

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) intravenous up to 30 ng/kg/min for 72 hours after surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8229122

Group type: EXPERIMENTAL
Intervention: 160 mg/d of megestrol acetate
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 800 mg/d of megestrol acetate
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 1,600 mg/d of megestrol acetate
Number of subjects: 131
Study: 3782653

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-modified ragweed extract administered via weekly injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyethylene glycol-modified ragweed extract administered via daily injections until adverse reaction, then switched to weekly schedule
Number of subjects: 50
Study: 29128682

Group type: EXPERIMENTAL
Intervention: Dedicated eyelid cleanser (TheraTears® SteriLid®)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Diluted baby shampoo (Johnson's® No More Tears®)
Number of subjects: 43
Study: 27342141

Group type: EXPERIMENTAL
Intervention: Proactive enrollment in quitline
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Provider suggestion to use quitline
Number of subjects: 1980

Group type: COMPARATOR
Intervention: No enrollment or suggestion
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: Quitline users (all types)
Number of subjects: 1980
Study: 24022270

Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP) 150 mg or 300 mg, administered subcutaneously every four weeks for 52 weeks
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo, administered subcutaneously every four weeks for 52 weeks
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 24211753

Group type: EXPERIMENTAL
Intervention: Baseline KEEP screening for CKD
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Follow-up KEEP screening for CKD
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Follow-up KEEP for patients who tested positive for CKD at baseline
Number of subjects: 434
Study: 21383045

Group type: EXPERIMENTAL
Intervention: MK-3207 200 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: MK-3207 100 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: MK-3207 10 mg
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 19123307

Group type: EXPERIMENTAL
Intervention: SRP + laser irradiation
Number of subjects: 13

Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 13
Study: 16796898

Group type: EXPERIMENTAL
Intervention: Guided pin axial position fluoroscopy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pedicle axial fluoroscopy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anteroposterior fluoroscopy
Number of subjects: 80
Study: 14564253

Group type: EXPERIMENTAL
Intervention: Preincisional remifentanil (0.2 microg kg(‐1) min(‐1) over 5 minutes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Postincisional remifentanil (0.5 microg kg(‐1) min(‐1) for 50 minutes, then 0.25 microg kg(‐1) min(‐1))
Number of subjects: 48
Study: 11082723

Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant chemotherapy (arm B)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 226
Study: 8931343

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1410157

Group type: EXPERIMENTAL
Intervention: Low nicotine delivery cigarettes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Medium nicotine delivery cigarettes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Denicotinised cigarette
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-smoking control condition
Number of subjects: 39
Study: 3956056

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: All three regimens (Enprofylline, Theophylline, Saline)
Number of subjects: 6
Study: 31958991

Group type: EXPERIMENTAL
Intervention: Storytelling video intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Information-based written material (comparison group)
Number of subjects: 104
Study: 30220407

Group type: EXPERIMENTAL
Intervention: PAXG (cisplatin 30 mg/m2, nab-paclitaxel 150 mg/m2, gemcitabine 800 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 every 4 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine (nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: PAXG
Number of subjects: 83

Group type: COMPARATOR
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 83
Study: 27681755

Group type: EXPERIMENTAL
Intervention: SIB-VMAT 55 Gy in 25 consecutive 2.2-Gy fractions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SIB-VMAT 60 Gy in 2.4-Gy fractions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both dose levels of SIB-VMAT
Number of subjects: 70
Study: 25439206

Group type: EXPERIMENTAL
Intervention: Conventional CSF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Er:YAG laser‐aided CSF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CSF groups
Number of subjects: 24
Study: 22992240

Group type: EXPERIMENTAL
Intervention: Immediate access to Breathlessness Support Service (BSS) in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard best practice and access to BSS after a waiting time of six weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate access to BSS in addition to standard care
Number of subjects: 0
Study: 21174285

Group type: EXPERIMENTAL
Intervention: PCVDP (active clinics)
Number of subjects: 4315

Group type: COMPARATOR
Intervention: Control group (non-PCVDP clinics)
Number of subjects: 4315
Study: 18575220

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 172

Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel
Number of subjects: 172
Study: 19298572

Group type: EXPERIMENTAL
Intervention: FPANS 200 microg bd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FPANS 200 microg od
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15036850

Group type: EXPERIMENTAL
Intervention: Supine Positioning
Number of subjects: 28

Group type: COMPARATOR
Intervention: Prone Positioning
Number of subjects: 28
Study: 11494543

Group type: EXPERIMENTAL
Intervention: Prolonged IFN therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN-beta therapy twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN-beta therapy daily for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of IFN-alpha and IFN-beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard IFN therapy
Number of subjects: 0
Study: 9593129

Group type: EXPERIMENTAL
Intervention: Cefdinir (300 mg twice a day for 5 days)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Penicillin V (250 mg four times a day for 10 days)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 558

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 558
Study: 7923322

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1809
Study: 3170403

Group type: EXPERIMENTAL
Intervention: Phasic negative pressure changes at the oropharynx (OP) simulating inspiratory resistive loading
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phasic negative pressure changes at the oropharynx (OP) simulating expiratory resistive unloading
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phasic negative pressure changes at the oropharynx (OP) simulating elastic loading
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phasic positive pressure changes at the oropharynx (OP) simulating inspiratory resistive unloading
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phasic positive pressure changes at the oropharynx (OP) simulating expiratory resistive loading
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Loading via tracheostomy with similar pressures
Number of subjects: 11
Study: 31589545

Group type: EXPERIMENTAL
Intervention: Children with Cochlear Implants (CCIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postlingually deaf adults with Cochlear Implants (CIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Hearing (NH) listeners
Number of subjects: 0
Study: 29850937

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (pre-hemodialysis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (post-hemodialysis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg (healthy subjects)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AR-C124910XX (pre-hemodialysis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AR-C124910XX (post-hemodialysis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AR-C124910XX (healthy subjects)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ticagrelor (all treatments)
Number of subjects: 27
Study: 27362956

Group type: EXPERIMENTAL
Intervention: High BMI group (Q4)
Number of subjects: 38810

Group type: EXPERIMENTAL
Intervention: High WC group
Number of subjects: 38810

Group type: COMPARATOR
Intervention: Low BMI group (Q1)
Number of subjects: 38810
Study: 25230867

Group type: EXPERIMENTAL
Intervention: HVHF treatment (18 hours per day on days 1, 3, 5, 7)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: PiCCO + HVHF treatment
Number of subjects: 163

Group type: COMPARATOR
Intervention: HVHF and PiCCO + HVHF groups
Number of subjects: 163
Study: 22412215

Group type: EXPERIMENTAL
Intervention: Mnemonic device presentation (30 minutes)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no mnemonic presentation before examination)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Survey administered to both groups
Number of subjects: 95
Study: 19291790

Group type: EXPERIMENTAL
Intervention: CIFN 9 microg/day and RBV
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: CIFN 15 microg/day and RBV
Number of subjects: 487
Study: 17690799

Group type: EXPERIMENTAL
Intervention: Twelve-step facilitation (TSF)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy (ICBT)
Number of subjects: 148
Study: 16218176

Group type: EXPERIMENTAL
Intervention: Once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 200
Study: 12117728

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) 70 mg transdermally daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (rhCG) 250 microg twice weekly
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (for both DHT and rhCG studies)
Number of subjects: 53
Study: 10201608

Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft transplantation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Mitomycin C with conjunctival flap
Number of subjects: 81
Study: 7776454

Group type: EXPERIMENTAL
Intervention: Modified ileal ureter (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard ileal ureter (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of renal function between group 1 and group 2 (without reflux)
Number of subjects: 50
Study: 2104071

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 388053

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) treatment, 2 units of TF administered subcutaneously on days 1 and 15
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) treatment
Number of subjects: 13
Study: 31479138

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR target 1.8)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Standard-intensity warfarin (INR target 2.5)
Number of subjects: 1650
Study: 27484766

Group type: EXPERIMENTAL
Intervention: Aidi intravenous injection plus NP regimen (2 cycles)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aidi intratumor injection plus NP regimen (2 cycles)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (NP regimen only)
Number of subjects: 150
Study: 25933151

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine HCl + 1/200,000 epinephrine (10 mL)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 1% lidocaine HCl + 1/200,000 epinephrine (10 mL)
Number of subjects: 91

Group type: COMPARATOR
Intervention: 0.9% saline (10 mL)
Number of subjects: 91
Study: 24130124

Group type: EXPERIMENTAL
Intervention: Probable RBD
Number of subjects: 42
Study: 21504955

Group type: EXPERIMENTAL
Intervention: Trunk exercises on physio ball
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trunk exercises on plinth (Control)
Number of subjects: 30
Study: 19732673

Group type: EXPERIMENTAL
Intervention: Precomprehensive orthodontic treatment
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Postinterceptive orthodontic treatment
Number of subjects: 293

Group type: COMPARATOR
Intervention: Nonorthodontic comparison
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Overall and oral health QoL
Number of subjects: 293
Study: 17690795

Group type: EXPERIMENTAL
Intervention: Random alcohol testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (light passenger vehicle drivers)
Number of subjects: 0
Study: 15183620

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone (CD)
Number of subjects: 1850

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 1850
Study: 11600590

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hexarelin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9732919

Group type: EXPERIMENTAL
Intervention: Eradicating treatment (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eradicating treatment (Group 2 after initial follow-up)
Number of subjects: 20